ASTRAZENECA PLC
AZNCFDrugs in Pipeline
347
Phase 3 Programs
185
Upcoming Catalysts
29
Next Catalyst
This month
Market Overview
Stock performance and key metrics
29 upcoming, 1 past
Tezepelumab Phase 2 Est. Readout
Estimated primary completion for Tezepelumab trial (NCT06230354) in EGPA - Eosinophilic Granulomatosis With Polyangiitis. Topline data typically follows completion by weeks to months.
SourceAcalabrutinib Phase 2 Est. Readout
Estimated primary completion for Acalabrutinib trial (NCT04883437) in Grade 1 Follicular Lymphoma. Topline data typically follows completion by weeks to months.
SourceZibotentan/Dapagliflozin Phase 2 Est. Readout
Estimated primary completion for Zibotentan/Dapagliflozin trial (NCT06942910) in Chronic Kidney Disease With High Proteinuria. Topline data typically follows completion by weeks to months.
Source26 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Goserelin acetate
Breast Cancer
AZD9291 Dosing
Lung Cancer
insulin detemir
Type 2 Diabetes Mellitus
BGF MDI 320/28.8/9.6 μg
Asthma
Lenvatinib
Hepatocellular Carcinoma
Experimental: Tralokinumab
Uncontrolled Asthma
Baxdrostat/dapagliflozin
Chronic Kidney Disease and Hypertension
Capivasertib
Triple Negative Breast Neoplasms
AZD0901
Gastric Cancer
Durvalumab (MEDI4736)
Non Small Cell Lung Carcinoma NSCLC
BGF MDI 320/14.4/9.6 μg
COPD (Chronic Obstructive Pulmonary Disease)
Ramucirumab+ paclitaxel
Gastric Cancer
Dato-DXd
Metastatic Non-small Cell Lung Cancer
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
Chronic Obstructive Pulmonary Disease
Selumetinib
Neurofibromatosis 1
Roflumilast
Asthma
Glyburide
Diabetes
TC-5214
Major Depressive Disorder
Seloken ZOK/Toprol-XL
Heart Failure, Congestive
AZD7442
COVID-19
Ropivacaine
Anesthesia,Spinal
Chlorambucil
Untreated Chronic Lymphocytic Leukemia
Acalabrutinib
Phase I: Relapsed or Refractory B-cell Malignancies
Symbicort, used twice daily (b.i.d) and as needed (prn)
Asthma
AZD0120
Relapsed Refractory Multiple Myeloma
ARIMIDEX (anastrazole)
Breast Cancer
Camizestrant
Breast Cancer, Early Breast Cancer
exenatide twice daily
Type 2 Diabetes Mellitus
CP-675,206
Carcinoma, Non-small-cell Lung
Terbutaline
Asthma
NXY-059
Cerebral Stroke
Metformin IR
Diabetes Mellitus, Type 2
Taxane
Breast Cancer; HER2-positive; Metastatic
Sodium Zirconium Cyclosilicate (ZS) 5g
Hyperkalemia
Exenatide once weekly suspension
Diabetes Type 2
Elecoglipron
Type 2 Diabetes Mellitus
Osimertinib
Non-Small Cell Lung Cancer
Ciclesonide Nasal Spray
Rhinitis, Allergic, Seasonal
Tezepelumab
Asthma
Candesartan
Congestive Heart Failure
Nirsevimab
Lower Respiratory Tract Infection
Experimental: Tezepelumab
Asthma
formoterol
Stable Asthma
Puxitatug Samrotecan
Endometrial Cancer
Tremelimumab
Non Small Cell Lung Cancer NSCLC
Dapagliflozin 10 mg
Type 2 Diabetes Mellitus
Monalizumab
Squamous Cell Carcinoma of the Head and Neck
Ticagrelor 90 mg
Myocardial Infarction
Aclidinium bromide/formoterol Fixed-Dose Combination
COPD
Ticagrelor
Peripheral Artery Disease
Foscarnet sodium
HIV Infections
Pravastatin
Hypercholesterolemia
Symbicort pMDI
Asthma
Biological: Experimental: Tezepelumab
Severe Asthma
Quetiapine fumarate
Schizophrenia
Durvalumab
Triple Negative Breast Cancer
Rosuvastatin calcium
Coronary Arteriosclerosis
Anastrozole
Breast Cancer
Irinotecan
Neoplasms, Unknown Primary
Tamoxifen
Quality of Life
Omeprazole
Reflux Esophagitis
budesonide/formoterol Turbuhaler
Asthma
Quetiapine XR
Bipolar Disorder
Esomeprazole
GERD
Rosuvastatin
Hypercholesterolemia
fluticasone/salmeterol (Advair Diskus)
Asthma
Hydrochlorothiazide
Type 2 Diabetes Mellitus
budesonide/formoterol (Symbicort)
Asthma
budesonide/formoterol
Asthma
Dapagliflozin
Diabetes Mellitus, Type 2
pramlintide acetate
Overweight
BDA MDI HFO 160/180 μg
Asthma
Rilvegostomig
Biliary Tract Cancer
Formoterol Fumarate
Chronic Obstructive Pulmonary Disease
Exenatide Once Weekly
Type 2 Diabetes Mellitus
Symbicort
Asthma
Budesonide/formoterol pMDI
Asthma
Saxagliptin-Metformin XR
Polycystic Ovary Syndrome
R-miniCHOP + Acalabrutinib
Large B-cell Lymphoma
HFA MDI
Asthma
Quetiapine
Psychotic Disorders
Domvanalimab
Non-Small Cell Lung Cancer
DAPA/MET XR
Diabetes Prevention in Women After GDM Who Are at High-risk
75mg selumetinib
Metastatic
Tamoxifen alone
Early-stage Breast Cancer
biphasic insulin aspart
Diabetes Mellitus, Type 2
AZD9833
Advanced ER-Positive HER2-Negative Breast Cancer
Saracatinib
Ovarian Cancer
olaparib
Colorectal Cancer
fluticasone/salmeterol (Advair)
Asthma
Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy
Asthma
Adjuvant durvalumab
Non Small Cell Lung Cancer
Ceralasertib
Advanced or Metastatic NSCLC
Symbicort pMDI + budesonide HFA pMDI
Asthma
Luteinizing hormone-releasing hormone (LHRH) agonist
ER-Positive HER2-Negative Breast Cancer
Durvalumab +Tremelimumab
Non Small Cell Lung Carcinoma NSCLC
Formoterol (OT)
Chronic Obstructive Pulmonary Disease
Tralokinumab
Asthma
Esomeprazole (Nexium)
Gastroesophageal Reflux Disease (GERD)
Ciclesonide
Asthma
Cisplatin/ Etoposide
Non-Small Cell Lung Cancer
Gefitinib
NSCLC
Saxagliptin
Type 2 Diabetes
candesartan cilexetil
Type 1 Diabetes
AZD9291 80 mg/40 mg
Stage IB-IIIA Non-small Cell Lung Carcinoma
AZD0780
Cardiovascular Disease
Alendronate sodium
Breast Cancer
Baxdrostat
Primary Hyperaldosteronism
Anastrozole (Arimidex)
Breast Cancer
fluticasone
Asthma
savolitinib
Carcinoma
Open Label Run In Esomeprazole
Gastroesophageal Reflux Disease (GERD)
Esomeprazole IV
Gastrointestinal Hemorrhage
MEDI4736 (Durvalumab)
Advanced Solid Malignancies
Paroxetine
Generalized Anxiety Disorder
Benralizumab 30 mg SC + Mometasone Furoate
Nasal Polyposis
Ethyl-eicosapentaenoic acid (EPA)
Schizophrenia
Sodium Zirconium Cyclosilicate 5g
Hyperkalemia
Esomeprazole 20 mg
Gastric Ulcer
fostamatinib
Rheumatoid Arthritis
AC2993
Diabetes Mellitus, Non-Insulin-Dependent
Dapagliflozin 10 milligram (mg)
COVID-19
Quetiapine Fumarate Sustained Release
Major Depressive Disorder
Misoprostol
Postpartum Hemorrhage
Extended release quetiapine (quetiapine XR)
Bipolar Disorder
Tozorakimab
Asthma
FG-4592
Anemia
Metformin XR
Type 2 Diabetes
budesonide (Pulmicort)
Chronic Obstructive Pulmonary Disease
AZD0486
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Rosuvastatin 20mg
Homozygous Familial Hypercholesterolemia (HoFH)
budesonide and budesonide/formoterol
Asthma
Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)
Schizophrenia
Ipratropium bromide
Asthma
fluticasone/salmeterol
Asthma
Aclidinium bromide
Chronic Obstructive Pulmonary Disease
Aclidinium Bromide/Formoterol Fumarate
Chronic Obstructive Pulmonary Disease (COPD)
Chemoimmunotherapy
Chronic Lymphocytic Leukemia
Fulvestrant 500mg
Breast Neoplasm Female
Olaparib 300mg tablets
Newly Diagnosed
MEDI4736 (Durvalumab)+Tremelimumab
Non-Small-Cell Lung Carcinoma NSCLC
rosiglitazone
Diabetes Mellitus, Type 2
AZD0585
Hypertriglyceridemia
Budesonide HFA
Asthma
Gefitinib or Docetaxel
Non-Small Cell Lung Cancer
Androgen blockade + radiation therapy
Prostate Cancer
Esomeprazole 40 mg
Gastric Ulcer
AZD 1222
COVID-19
Surovatamig
Untreated Follicular Lymphoma
Paclitaxel and Carboplatin
Breast Cancer
Datopotamab Deruxtecan
Non-Small Cell Lung Cancer
R-mini-CHOP
Large B-cell Lymphoma
SSRI/Venlafaxine
Major Depressive Disorder
Cediranib Maleate
Advanced Malignant Solid Neoplasm
Pegylated Liposomal Doxorubicin Hydrochloride
Fallopian Tube Clear Cell Adenocarcinoma
Cediranib
Renal Cell Carcinoma
Ticagrelor mashed pills
Acute Coronary Syndrome
AZD2265
Metastatic Castration-resistant Prostate Cancer
quetiapine fumarate or valproate
Bipolar Disorder
Administration of quetiapine XR
Schizophrenia
MEDI4736
Ovarian
Quetiapine SR
Anxiety Disorders
Glycopyrronium/Formoterol Fumarate
Chronic Obstructive Pulmonary Disease COPD
D961H sachet 10 mg
Gastric Ulcer (GU)
Seroquel SR
Schizophrenia
NKTR-118
Opioid-Induced Constipation (OIC)
Saruparib
Metastatic Castration-Sensitive Prostate Cancer
Eribulin
Breast Cancer
Volrustomig
Unresectable Pleural Mesothelioma
MEDI8897
Respiratory Syncytial Virus Infections
AZD9291
Non-Small Cell Lung Cancer
Benralizumab
Asthma
BFF MDI 160/9.6 μg BID (320/19.2μg/day)
Asthma
Symbicort Turbuhaler
Asthma
Terbutaline Turbuhaler
Asthma
candsartan cilexetil
Pediatric Hypertension
exenatide
Type 2 Diabetes Mellitus
Ribociclib
ER-Positive HER2-Negative Breast Cancer
MEDI3250
Healthy Japanese Children Age 2 Years Through 6 Years
Formoterol Turbuhaler
Chronic Obstructive Pulmonary Disease
Durvalumab + Chemotherapy phase
Advanced or Recurrent Endometrial Cancer
Anifrolumab
Active Systemic Lupus Erythematosus
metoprolol succinate
Hypertension
Lithium
Mania
Anastozole (Arimidex)
Breast Cancer
80mg Osimertinib
Non-small Cell Lung Cancer (NSCLC)
CIN-107 2 mg dosing
Primary Aldosteronism
MEDI4736 + Tremelimumab
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Tomudex
Inoperable or Recurrent Rectal Cancer
AZD6489
RSV Respiratory Syncytial Virus
Arimidex 1 mg
McCune-Albright Syndrome
AZD0837
Persistent or Permanent Non-valvular Atrial Fibrillation
AZD7798
Moderate to Severe Crohn's Disease
AZD7624 1.0 mg
Chronic Obstructive Pulmonary Disease COPD
Tesaglitazar
Type 2 Diabetes
ZD4054
Non Small Cell Lung Cancer
Aclidinium bromide and formoterol
Chronic Obstructive Pulmonary Disease (COPD)
Selumetinib granule formulation
Neurofibromatosis Type 1
AZD2265 (FPI-2265)
Metastatic Prostate Cancer
MEDI3506
Diabetic Kidney Disease
AZD4635
Progressive Metastatic Castrate-Resistant Prostate Cancer
Selumetinib+Docetaxel
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Febuxostat
Asymptomatic Hyperuricemia
AZD1386
Pain
gefitinib (Iressa)
Neoplasms, Squamous Cell
Eplontersen
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
RDEA3170
Gout and Asymptomatic Hyperuricemia
AZD5863
Gastric Cancer
AZD3632
Acute Lymphoblastic Leukaemia
Adavosertib
Uterine Serous Carcinoma
AZD8233
Dyslipidaemia
AZD4144
Sepsis
AZD0516
Metastatic Prostate Cancer
Acalabrutinib monotherapy
Mantle-cell Lymphoma
MEDI4736 in combination with nab-paclitaxel and gemcitabine
Metastatic Pancreatic Ductal Adenocarcinoma
AZD6234
Endocrinology
Datopotamab Deruxtecan (Dato-DXd)
Carcinoma, Non-Small-Cell Lung
exenatide once monthly suspension
Type 2 Diabetes
Amivantamab
Non-Small Cell Lung Cancer (NSCLC)
Zibotentan
Chronic Kidney Disease
AZD5672
Rheumatoid Arthritis
AZD2281
Ovarian Carcinoma
Zibotentan + dapagliflozin
Liver Cirrhosis
tralokinumab cohort 1
Idiopathic Pulmonary Fibrosis
Anastrazole
Breast Cancer
AZD2811
Small-Cell Lung Cancer
AZD1419
Asthma
AZD 2014
Diffuse Large B-Cell Lymphoma
AZD6793
Chronic Obstructive Pulmonary Disease (COPD)
AZD8359
Metastatic Prostate Cancer
AZD9750
Prostate Cancer
AZD7268
Major Depressive Disorder
AZD5305
Metastatic Prostate Cancer
AZD1236
Chronic Obstructive Pulmonary Disease
AZD3480
Alzheimer Disease
AZD0292
Bronchiectasis With Pseudomonas Aeruginosa Colonization
AZD6765
Depression
AZD9550
Obesity or Overweight
AZD4547
FGFR Inhibition, Pharmacokinetics, Biomarkers
AZD5423
Asthma
AZD8965 low dose
Idiopathic Pulmonary Fibrosis (IPF)
AZD2389
Liver Fibrosis
AZD1446
Mild to Moderate Alzheimer's Disease
AZD3470
Advanced Solid Tumors That Are MTAP Deficient
AZD5148
Clostridioides Difficile Infection
CIN-107
Hypertension
AZD1981
Chronic Obstructive Pulmonary Disease
AZD7325
Anxiety Disorders
Oleclumab
Non-Small Cell Lung Cancer
Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
Pulmonary Disease, Chronic Obstructive
AZD8848
Allergic Rhinitis
Drug: carboplatin
Ovarian Cancer
ZD4054 15 mg
Prostate Cancer
Verinurad
Heart Failure With Preserved Ejection Fraction (HFpEF)
MEDI0382 100 μg
Type 2 Diabetes
AZD3199
Asthma
AZD2516, 5 mg
Reflux
AZD5004
Obesity or Overweight
AZD2171
Gastrointestinal Stromal Tumors
Zibotentan/Dapagliflozin
Chronic Kidney Disease With High Proteinuria
Glipizide
Type II Diabetes Mellitus
AZD6244
Metastatic Colorectal Cancer
AZD5069
Bronchiectasis
Caprelsa (vandetanib)
Pancreatic Cancer
Nab-paclitaxel+carboplatin
Non-small Cell Lung Cancer NSCLC
gefitinib (IRESSA™, ZD1839)
Breast Cancer
Omega-3 carboxylic acids
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
AZD1305
Left Ventricle Function
AZD3355
Reflux Episodes
LAS100977
Chronic Obstructive Pulmonary Disease (COPD)
AZD4831
Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
MEDI-546
Systemic Lupus Erythematosus
AZD4604
Asthma
Ciclesonide HFA
Rhinitis, Allergic, Seasonal
GC012F Injection
Refractory Systemic Lupus Erythematosus
Rucaparib
Adenocarcinoma of the Oesophagus
AZD4877
Bladder Cancer
AZD4956
Solid Tumours
Atirmociclib
Advanced Breast Cancer
AZD9773
Severe Sepsis
AZD0305
Multiple Myeloma
Durvalumab / Tremelimumab Combination Therapy
Pediatric Cancer
AZD6765 iv
Major Depressive Disorder
AZD1656
Type II Diabetes
AZD9567
Rheumatoid Arthritis
AZD0865
GERD With Erosive Esophagitis
Gefitinib 250mg
Lung Cancer
AZD2423
Chronic Obstructive Pulmonary Disease
AZD2066
Pain
AZD4573
Relapsed/Refractory Peripheral T-cell Lymphoma
[18F]AZD4694
Alzheimer's Disease
CP-675,206 (Tremelimumab)
Colorectal Neoplasms
AZD1222
COVID-19
AZD9668
Chronic Obstructive Pulmonary Disease (COPD)
AZD0530
Ovarian Neoplasms
MEDI7183 low dose
Ulcerative Colitis
Quetiapine fumarate (Seroquel)
Major Depressive Disorder
Osimertinib 80 MG [Tagrisso]
Locally Advanced or Metastatic NSCLC
Escalating dose of Casodex from 50mg daily to 150 mg daily
Prostate Cancer
quetiapine (Seroquel) XR
Bipolar Depression
Dapagliflozin Tablet
Weight Loss
Consolidative Durvalumab
Non Small Cell Lung Cancer
MEDI9447
Triple Negative Breast Cancer
P-Sam
Adenoid Cystic Carcinoma
AZD2014
Metastatic Breast Cancer
Fulvestrant injection
ER+ Breast Cancer
SNDX-6352
Unresectable Intrahepatic Cholangiocarcinoma
Acalabrutinib 2x100 MG Oral Capsule + alloSCT
Chronic Lymphocytic Leukemia
ICI 182,780 (Faslodex)
Systemic Lupus Erythematosus
Itacitinib
Lung Cancer
Axicabtagene Ciloleucel
B-Cell Non-Hodgkin Lymphoma
R-CHOP
Diffuse Large B Cell Lymphoma
Tremelimumab Plus Durvalumab (MEDI4736)
Hepatocellular Carcinoma (HCC)
Etoposide with Carboplatin or Cisplatin
Extensive-Stage Small-Cell Lung Cancer
Standard-of-Care
HER2-positive Early Breast Cancer
Durvalumab + Tremelimumab + metronomic Vinorelbine
Advanced Solid Tumours
rAd26-S
COVID-19
Durvalumab (Cohort 1-3)
Urothelial Carcinoma
AZD1775
Uterine Cancer
Lymphodepleting chemotherapy
Refractory Aggressive B-cell Lymphomas
Testosterone Enanthate
Castration-Resistant Prostate Carcinoma
Benralizumab 100 mg
Pulmonary Disease, Chronic Obstructive
Vigil
Breast Cancer
vandetanib induction
Lung Cancer
AZD4017 and prednisolone
Iatrogenic Cushing's Disease
TEW-7197
Non-Small Cell Lung Cancer Metastatic
Physicians Choice systemic chemotherapy
Breast Cancer
DS-8201a
Colorectal Neoplasm
AZD5363
Non-small Cell Lung Cancer Metastatic
Neoantigen DNA vaccine
Extensive-stage Small Cell Lung Cancer
Durvalumab and Tremelimumab
Metastatic Adult Soft Tissue Sarcoma
AZD4547 / anastrozole or letrozole
Breast Cancer
Carboplatin or Cisplatin
Small Cell Lung Cancer
Bevespi
Chronic Obstructive Pulmonary Disease
Formoterol/Budesonide
Obstructive Airway Disease
Olaparib Pill
High Grade Serous Carcinoma
carboplatin AUC 2/paclitaxel
Esophageal Adenocarcinoma
CFI-400945
Breast Cancer
AZD4045
Relapsed or Refractory Multiple Myeloma
cis Platinum
Lung Cancer Stage II
AZD8931
Metastatic Colorectal Cancer
Metoprolol
Breast Cancer
budesonide/formoterol, 2x 200/6 microgram. 4 times daily
Chronic Obstructive Pulmonary Disease
Gefitinib retreatment
Carcinoma, Non-Small-Cell Lung
Fulvestrant + ZACTIMA
Metastatic Breast Cancer
Dapagliflozin 10Mg Tab
Chronic Kidney Diseases
Chemoradiotherapy arm
Oropharyngeal Squamous Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Goserelin acetate | Phase 3 | Breast Cancer | - | - |
AZD9291 Dosing | Phase 3 | Lung Cancer | - | - |
insulin detemir | Phase 3 | Type 2 Diabetes Mellitus | - | - |
BGF MDI 320/28.8/9.6 μg | Phase 3 | Asthma | - | - |
Lenvatinib | Phase 3 | Hepatocellular Carcinoma | - | - |
Experimental: Tralokinumab | Phase 3 | Uncontrolled Asthma | - | - |
Baxdrostat/dapagliflozin | Phase 3 | Chronic Kidney Disease and Hypertension | - | - |
Capivasertib | Phase 3 | Triple Negative Breast Neoplasms | - | - |
AZD0901 | Phase 3 | Gastric Cancer | - | - |
Durvalumab (MEDI4736) | Phase 3 | Non Small Cell Lung Carcinoma NSCLC | - | - |
BGF MDI 320/14.4/9.6 μg | Phase 3 | COPD (Chronic Obstructive Pulmonary Disease) | - | - |
Ramucirumab+ paclitaxel | Phase 3 | Gastric Cancer | - | - |
Dato-DXd | Phase 3 | Metastatic Non-small Cell Lung Cancer | - | - |
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Selumetinib | Phase 3 | Neurofibromatosis 1 | - | - |
Roflumilast | Phase 3 | Asthma | - | - |
Glyburide | Phase 3 | Diabetes | - | - |
TC-5214 | Phase 3 | Major Depressive Disorder | - | - |
Seloken ZOK/Toprol-XL | Phase 3 | Heart Failure, Congestive | - | - |
AZD7442 | Phase 3 | COVID-19 | - | - |
Ropivacaine | Phase 3 | Anesthesia,Spinal | - | - |
Chlorambucil | Phase 3 | Untreated Chronic Lymphocytic Leukemia | - | - |
Acalabrutinib | Phase 3 | Phase I: Relapsed or Refractory B-cell Malignancies | - | - |
Symbicort, used twice daily (b.i.d) and as needed (prn) | Phase 3 | Asthma | - | - |
AZD0120 | Phase 3 | Relapsed Refractory Multiple Myeloma | - | - |
ARIMIDEX (anastrazole) | Phase 3 | Breast Cancer | - | - |
Camizestrant | Phase 3 | Breast Cancer, Early Breast Cancer | - | - |
exenatide twice daily | Phase 3 | Type 2 Diabetes Mellitus | - | - |
CP-675,206 | Phase 3 | Carcinoma, Non-small-cell Lung | - | - |
Terbutaline | Phase 3 | Asthma | - | - |
NXY-059 | Phase 3 | Cerebral Stroke | - | - |
Metformin IR | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Taxane | Phase 3 | Breast Cancer; HER2-positive; Metastatic | - | - |
Sodium Zirconium Cyclosilicate (ZS) 5g | Phase 3 | Hyperkalemia | - | - |
Exenatide once weekly suspension | Phase 3 | Diabetes Type 2 | - | - |
Elecoglipron | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Osimertinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Ciclesonide Nasal Spray | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
Tezepelumab | Phase 3 | Asthma | - | - |
Candesartan | Phase 3 | Congestive Heart Failure | - | - |
Nirsevimab | Phase 3 | Lower Respiratory Tract Infection | - | - |
Experimental: Tezepelumab | Phase 3 | Asthma | - | - |
formoterol | Phase 3 | Stable Asthma | - | - |
Puxitatug Samrotecan | Phase 3 | Endometrial Cancer | - | - |
Tremelimumab | Phase 3 | Non Small Cell Lung Cancer NSCLC | - | - |
Dapagliflozin 10 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Monalizumab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Ticagrelor 90 mg | Phase 3 | Myocardial Infarction | - | - |
Aclidinium bromide/formoterol Fixed-Dose Combination | Phase 3 | COPD | - | - |
Ticagrelor | Phase 3 | Peripheral Artery Disease | - | - |
Foscarnet sodium | Phase 3 | HIV Infections | - | - |
Pravastatin | Phase 3 | Hypercholesterolemia | - | - |
Symbicort pMDI | Phase 3 | Asthma | - | - |
Biological: Experimental: Tezepelumab | Phase 3 | Severe Asthma | - | - |
Quetiapine fumarate | Phase 3 | Schizophrenia | - | - |
Durvalumab | Phase 3 | Triple Negative Breast Cancer | - | - |
Rosuvastatin calcium | Phase 3 | Coronary Arteriosclerosis | - | - |
Anastrozole | Phase 3 | Breast Cancer | - | - |
Irinotecan | Phase 3 | Neoplasms, Unknown Primary | - | - |
Tamoxifen | Phase 3 | Quality of Life | - | - |
Omeprazole | Phase 3 | Reflux Esophagitis | - | - |
budesonide/formoterol Turbuhaler | Phase 3 | Asthma | - | - |
Quetiapine XR | Phase 3 | Bipolar Disorder | - | - |
Esomeprazole | Phase 3 | GERD | - | - |
Rosuvastatin | Phase 3 | Hypercholesterolemia | - | - |
fluticasone/salmeterol (Advair Diskus) | Phase 3 | Asthma | - | - |
Hydrochlorothiazide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
budesonide/formoterol (Symbicort) | Phase 3 | Asthma | - | - |
budesonide/formoterol | Phase 3 | Asthma | - | - |
Dapagliflozin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
pramlintide acetate | Phase 3 | Overweight | - | - |
BDA MDI HFO 160/180 μg | Phase 3 | Asthma | - | - |
Rilvegostomig | Phase 3 | Biliary Tract Cancer | - | - |
Formoterol Fumarate | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Exenatide Once Weekly | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Symbicort | Phase 3 | Asthma | - | - |
Budesonide/formoterol pMDI | Phase 3 | Asthma | - | - |
Saxagliptin-Metformin XR | Phase 3 | Polycystic Ovary Syndrome | - | - |
R-miniCHOP + Acalabrutinib | Phase 3 | Large B-cell Lymphoma | - | - |
HFA MDI | Phase 3 | Asthma | - | - |
Quetiapine | Phase 3 | Psychotic Disorders | - | - |
Domvanalimab | Phase 3 | Non-Small Cell Lung Cancer | - | - |
DAPA/MET XR | Phase 3 | Diabetes Prevention in Women After GDM Who Are at High-risk | - | - |
75mg selumetinib | Phase 3 | Metastatic | - | - |
Tamoxifen alone | Phase 3 | Early-stage Breast Cancer | - | - |
biphasic insulin aspart | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
AZD9833 | Phase 3 | Advanced ER-Positive HER2-Negative Breast Cancer | - | - |
Saracatinib | Phase 3 | Ovarian Cancer | - | - |
olaparib | Phase 3 | Colorectal Cancer | - | - |
fluticasone/salmeterol (Advair) | Phase 3 | Asthma | - | - |
Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy | Phase 3 | Asthma | - | - |
Adjuvant durvalumab | Phase 3 | Non Small Cell Lung Cancer | - | - |
Ceralasertib | Phase 3 | Advanced or Metastatic NSCLC | - | - |
Symbicort pMDI + budesonide HFA pMDI | Phase 3 | Asthma | - | - |
Luteinizing hormone-releasing hormone (LHRH) agonist | Phase 3 | ER-Positive HER2-Negative Breast Cancer | - | - |
Durvalumab +Tremelimumab | Phase 3 | Non Small Cell Lung Carcinoma NSCLC | - | - |
Formoterol (OT) | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Tralokinumab | Phase 3 | Asthma | - | - |
Esomeprazole (Nexium) | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
Ciclesonide | Phase 3 | Asthma | - | - |
Cisplatin/ Etoposide | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Gefitinib | Phase 3 | NSCLC | - | - |
Saxagliptin | Phase 3 | Type 2 Diabetes | - | - |
candesartan cilexetil | Phase 3 | Type 1 Diabetes | - | - |
AZD9291 80 mg/40 mg | Phase 3 | Stage IB-IIIA Non-small Cell Lung Carcinoma | - | - |
AZD0780 | Phase 3 | Cardiovascular Disease | - | - |
Alendronate sodium | Phase 3 | Breast Cancer | - | - |
Baxdrostat | Phase 3 | Primary Hyperaldosteronism | - | - |
Anastrozole (Arimidex) | Phase 3 | Breast Cancer | - | - |
fluticasone | Phase 3 | Asthma | - | - |
savolitinib | Phase 3 | Carcinoma | - | - |
Open Label Run In Esomeprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
Esomeprazole IV | Phase 3 | Gastrointestinal Hemorrhage | - | - |
MEDI4736 (Durvalumab) | Phase 3 | Advanced Solid Malignancies | - | - |
Paroxetine | Phase 3 | Generalized Anxiety Disorder | - | - |
Benralizumab 30 mg SC + Mometasone Furoate | Phase 3 | Nasal Polyposis | - | - |
Ethyl-eicosapentaenoic acid (EPA) | Phase 3 | Schizophrenia | - | - |
Sodium Zirconium Cyclosilicate 5g | Phase 3 | Hyperkalemia | - | - |
Esomeprazole 20 mg | Phase 3 | Gastric Ulcer | - | - |
fostamatinib | Phase 3 | Rheumatoid Arthritis | - | - |
AC2993 | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
Dapagliflozin 10 milligram (mg) | Phase 3 | COVID-19 | - | - |
Quetiapine Fumarate Sustained Release | Phase 3 | Major Depressive Disorder | - | - |
Misoprostol | Phase 3 | Postpartum Hemorrhage | - | - |
Extended release quetiapine (quetiapine XR) | Phase 3 | Bipolar Disorder | - | - |
Tozorakimab | Phase 3 | Asthma | - | - |
FG-4592 | Phase 3 | Anemia | - | - |
Metformin XR | Phase 3 | Type 2 Diabetes | - | - |
budesonide (Pulmicort) | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
AZD0486 | Phase 3 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | - | - |
Rosuvastatin 20mg | Phase 3 | Homozygous Familial Hypercholesterolemia (HoFH) | - | - |
budesonide and budesonide/formoterol | Phase 3 | Asthma | - | - |
Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) | Phase 3 | Schizophrenia | - | - |
Ipratropium bromide | Phase 3 | Asthma | - | - |
fluticasone/salmeterol | Phase 3 | Asthma | - | - |
Aclidinium bromide | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Aclidinium Bromide/Formoterol Fumarate | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Chemoimmunotherapy | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Fulvestrant 500mg | Phase 3 | Breast Neoplasm Female | - | - |
Olaparib 300mg tablets | Phase 3 | Newly Diagnosed | - | - |
MEDI4736 (Durvalumab)+Tremelimumab | Phase 3 | Non-Small-Cell Lung Carcinoma NSCLC | - | - |
rosiglitazone | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
AZD0585 | Phase 3 | Hypertriglyceridemia | - | - |
Budesonide HFA | Phase 3 | Asthma | - | - |
Gefitinib or Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Androgen blockade + radiation therapy | Phase 3 | Prostate Cancer | - | - |
Esomeprazole 40 mg | Phase 3 | Gastric Ulcer | - | - |
AZD 1222 | Phase 3 | COVID-19 | - | - |
Surovatamig | Phase 3 | Untreated Follicular Lymphoma | - | - |
Paclitaxel and Carboplatin | Phase 3 | Breast Cancer | - | - |
Datopotamab Deruxtecan | Phase 3 | Non-Small Cell Lung Cancer | - | - |
R-mini-CHOP | Phase 3 | Large B-cell Lymphoma | - | - |
SSRI/Venlafaxine | Phase 3 | Major Depressive Disorder | - | - |
Cediranib Maleate | Phase 3 | Advanced Malignant Solid Neoplasm | - | - |
Pegylated Liposomal Doxorubicin Hydrochloride | Phase 3 | Fallopian Tube Clear Cell Adenocarcinoma | - | - |
Cediranib | Phase 3 | Renal Cell Carcinoma | - | - |
Ticagrelor mashed pills | Phase 3 | Acute Coronary Syndrome | - | - |
AZD2265 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
quetiapine fumarate or valproate | Phase 3 | Bipolar Disorder | - | - |
Administration of quetiapine XR | Phase 3 | Schizophrenia | - | - |
MEDI4736 | Phase 3 | Ovarian | - | - |
Quetiapine SR | Phase 3 | Anxiety Disorders | - | - |
Glycopyrronium/Formoterol Fumarate | Phase 3 | Chronic Obstructive Pulmonary Disease COPD | - | - |
D961H sachet 10 mg | Phase 3 | Gastric Ulcer (GU) | - | - |
Seroquel SR | Phase 3 | Schizophrenia | - | - |
NKTR-118 | Phase 3 | Opioid-Induced Constipation (OIC) | - | - |
Saruparib | Phase 3 | Metastatic Castration-Sensitive Prostate Cancer | - | - |
Eribulin | Phase 3 | Breast Cancer | - | - |
Volrustomig | Phase 3 | Unresectable Pleural Mesothelioma | - | - |
MEDI8897 | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
AZD9291 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Benralizumab | Phase 3 | Asthma | - | - |
BFF MDI 160/9.6 μg BID (320/19.2μg/day) | Phase 3 | Asthma | - | - |
Symbicort Turbuhaler | Phase 3 | Asthma | - | - |
Terbutaline Turbuhaler | Phase 3 | Asthma | - | - |
candsartan cilexetil | Phase 3 | Pediatric Hypertension | - | - |
exenatide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ribociclib | Phase 3 | ER-Positive HER2-Negative Breast Cancer | - | - |
MEDI3250 | Phase 3 | Healthy Japanese Children Age 2 Years Through 6 Years | - | - |
Formoterol Turbuhaler | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Durvalumab + Chemotherapy phase | Phase 3 | Advanced or Recurrent Endometrial Cancer | - | - |
Anifrolumab | Phase 3 | Active Systemic Lupus Erythematosus | - | - |
metoprolol succinate | Phase 3 | Hypertension | - | - |
Lithium | Phase 3 | Mania | - | - |
Anastozole (Arimidex) | Phase 3 | Breast Cancer | - | - |
80mg Osimertinib | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
CIN-107 2 mg dosing | Phase 2 | Primary Aldosteronism | - | - |
MEDI4736 + Tremelimumab | Phase 2 | Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck | - | - |
Tomudex | Phase 2 | Inoperable or Recurrent Rectal Cancer | - | - |
AZD6489 | Phase 2 | RSV Respiratory Syncytial Virus | - | - |
Arimidex 1 mg | Phase 2 | McCune-Albright Syndrome | - | - |
AZD0837 | Phase 2 | Persistent or Permanent Non-valvular Atrial Fibrillation | - | - |
AZD7798 | Phase 2 | Moderate to Severe Crohn's Disease | - | - |
AZD7624 1.0 mg | Phase 2 | Chronic Obstructive Pulmonary Disease COPD | - | - |
Tesaglitazar | Phase 2 | Type 2 Diabetes | - | - |
ZD4054 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Aclidinium bromide and formoterol | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Selumetinib granule formulation | Phase 2 | Neurofibromatosis Type 1 | - | - |
AZD2265 (FPI-2265) | Phase 2 | Metastatic Prostate Cancer | - | - |
MEDI3506 | Phase 2 | Diabetic Kidney Disease | - | - |
AZD4635 | Phase 2 | Progressive Metastatic Castrate-Resistant Prostate Cancer | - | - |
Selumetinib+Docetaxel | Phase 2 | Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV) | - | - |
Febuxostat | Phase 2 | Asymptomatic Hyperuricemia | - | - |
AZD1386 | Phase 2 | Pain | - | - |
gefitinib (Iressa) | Phase 2 | Neoplasms, Squamous Cell | - | - |
Eplontersen | Phase 2 | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | - | - |
RDEA3170 | Phase 2 | Gout and Asymptomatic Hyperuricemia | - | - |
AZD5863 | Phase 2 | Gastric Cancer | - | - |
AZD3632 | Phase 2 | Acute Lymphoblastic Leukaemia | - | - |
Adavosertib | Phase 2 | Uterine Serous Carcinoma | - | - |
AZD8233 | Phase 2 | Dyslipidaemia | - | - |
AZD4144 | Phase 2 | Sepsis | - | - |
AZD0516 | Phase 2 | Metastatic Prostate Cancer | - | - |
Acalabrutinib monotherapy | Phase 2 | Mantle-cell Lymphoma | - | - |
MEDI4736 in combination with nab-paclitaxel and gemcitabine | Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
AZD6234 | Phase 2 | Endocrinology | - | - |
Datopotamab Deruxtecan (Dato-DXd) | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
exenatide once monthly suspension | Phase 2 | Type 2 Diabetes | - | - |
Amivantamab | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
Zibotentan | Phase 2 | Chronic Kidney Disease | - | - |
AZD5672 | Phase 2 | Rheumatoid Arthritis | - | - |
AZD2281 | Phase 2 | Ovarian Carcinoma | - | - |
Zibotentan + dapagliflozin | Phase 2 | Liver Cirrhosis | - | - |
tralokinumab cohort 1 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Anastrazole | Phase 2 | Breast Cancer | - | - |
AZD2811 | Phase 2 | Small-Cell Lung Cancer | - | - |
AZD1419 | Phase 2 | Asthma | - | - |
AZD 2014 | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
AZD6793 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AZD8359 | Phase 2 | Metastatic Prostate Cancer | - | - |
AZD9750 | Phase 2 | Prostate Cancer | - | - |
AZD7268 | Phase 2 | Major Depressive Disorder | - | - |
AZD5305 | Phase 2 | Metastatic Prostate Cancer | - | - |
AZD1236 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
AZD3480 | Phase 2 | Alzheimer Disease | - | - |
AZD0292 | Phase 2 | Bronchiectasis With Pseudomonas Aeruginosa Colonization | - | - |
AZD6765 | Phase 2 | Depression | - | - |
AZD9550 | Phase 2 | Obesity or Overweight | - | - |
AZD4547 | Phase 2 | FGFR Inhibition, Pharmacokinetics, Biomarkers | - | - |
AZD5423 | Phase 2 | Asthma | - | - |
AZD8965 low dose | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
AZD2389 | Phase 2 | Liver Fibrosis | - | - |
AZD1446 | Phase 2 | Mild to Moderate Alzheimer's Disease | - | - |
AZD3470 | Phase 2 | Advanced Solid Tumors That Are MTAP Deficient | - | - |
AZD5148 | Phase 2 | Clostridioides Difficile Infection | - | - |
CIN-107 | Phase 2 | Hypertension | - | - |
AZD1981 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
AZD7325 | Phase 2 | Anxiety Disorders | - | - |
Oleclumab | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Aclidinium Bromide/Formoterol Fumarate 400/12μg BID | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
AZD8848 | Phase 2 | Allergic Rhinitis | - | - |
Drug: carboplatin | Phase 2 | Ovarian Cancer | - | - |
ZD4054 15 mg | Phase 2 | Prostate Cancer | - | - |
Verinurad | Phase 2 | Heart Failure With Preserved Ejection Fraction (HFpEF) | - | - |
MEDI0382 100 μg | Phase 2 | Type 2 Diabetes | - | - |
AZD3199 | Phase 2 | Asthma | - | - |
AZD2516, 5 mg | Phase 2 | Reflux | - | - |
AZD5004 | Phase 2 | Obesity or Overweight | - | - |
AZD2171 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Zibotentan/Dapagliflozin | Phase 2 | Chronic Kidney Disease With High Proteinuria | - | - |
Glipizide | Phase 2 | Type II Diabetes Mellitus | - | - |
AZD6244 | Phase 2 | Metastatic Colorectal Cancer | - | - |
AZD5069 | Phase 2 | Bronchiectasis | - | - |
Caprelsa (vandetanib) | Phase 2 | Pancreatic Cancer | - | - |
Nab-paclitaxel+carboplatin | Phase 2 | Non-small Cell Lung Cancer NSCLC | - | - |
gefitinib (IRESSA™, ZD1839) | Phase 2 | Breast Cancer | - | - |
Omega-3 carboxylic acids | Phase 2 | T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin) | - | - |
AZD1305 | Phase 2 | Left Ventricle Function | - | - |
AZD3355 | Phase 2 | Reflux Episodes | - | - |
LAS100977 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AZD4831 | Phase 2 | Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | - | - |
MEDI-546 | Phase 2 | Systemic Lupus Erythematosus | - | - |
AZD4604 | Phase 2 | Asthma | - | - |
Ciclesonide HFA | Phase 2 | Rhinitis, Allergic, Seasonal | - | - |
GC012F Injection | Phase 2 | Refractory Systemic Lupus Erythematosus | - | - |
Rucaparib | Phase 2 | Adenocarcinoma of the Oesophagus | - | - |
AZD4877 | Phase 2 | Bladder Cancer | - | - |
AZD4956 | Phase 2 | Solid Tumours | - | - |
Atirmociclib | Phase 2 | Advanced Breast Cancer | - | - |
AZD9773 | Phase 2 | Severe Sepsis | - | - |
AZD0305 | Phase 2 | Multiple Myeloma | - | - |
Durvalumab / Tremelimumab Combination Therapy | Phase 2 | Pediatric Cancer | - | - |
AZD6765 iv | Phase 2 | Major Depressive Disorder | - | - |
AZD1656 | Phase 2 | Type II Diabetes | - | - |
AZD9567 | Phase 2 | Rheumatoid Arthritis | - | - |
AZD0865 | Phase 2 | GERD With Erosive Esophagitis | - | - |
Gefitinib 250mg | Phase 2 | Lung Cancer | - | - |
AZD2423 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
AZD2066 | Phase 2 | Pain | - | - |
AZD4573 | Phase 2 | Relapsed/Refractory Peripheral T-cell Lymphoma | - | - |
[18F]AZD4694 | Phase 2 | Alzheimer's Disease | - | - |
CP-675,206 (Tremelimumab) | Phase 2 | Colorectal Neoplasms | - | - |
AZD1222 | Phase 2 | COVID-19 | - | - |
AZD9668 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AZD0530 | Phase 2 | Ovarian Neoplasms | - | - |
MEDI7183 low dose | Phase 2 | Ulcerative Colitis | - | - |
Quetiapine fumarate (Seroquel) | Phase 2 | Major Depressive Disorder | - | - |
Osimertinib 80 MG [Tagrisso] | Phase 2 | Locally Advanced or Metastatic NSCLC | - | - |
Escalating dose of Casodex from 50mg daily to 150 mg daily | Phase 2 | Prostate Cancer | - | - |
quetiapine (Seroquel) XR | Phase 2 | Bipolar Depression | - | - |
Dapagliflozin Tablet | Phase 2 | Weight Loss | - | - |
Consolidative Durvalumab | Phase 2 | Non Small Cell Lung Cancer | - | - |
MEDI9447 | Phase 2 | Triple Negative Breast Cancer | - | - |
P-Sam | Phase 2 | Adenoid Cystic Carcinoma | - | - |
AZD2014 | Phase 2 | Metastatic Breast Cancer | - | - |
Fulvestrant injection | Phase 2 | ER+ Breast Cancer | - | - |
SNDX-6352 | Phase 2 | Unresectable Intrahepatic Cholangiocarcinoma | - | - |
Acalabrutinib 2x100 MG Oral Capsule + alloSCT | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
ICI 182,780 (Faslodex) | Phase 2 | Systemic Lupus Erythematosus | - | - |
Itacitinib | Phase 2 | Lung Cancer | - | - |
Axicabtagene Ciloleucel | Phase 2 | B-Cell Non-Hodgkin Lymphoma | - | - |
R-CHOP | Phase 2 | Diffuse Large B Cell Lymphoma | - | - |
Tremelimumab Plus Durvalumab (MEDI4736) | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
Etoposide with Carboplatin or Cisplatin | Phase 2 | Extensive-Stage Small-Cell Lung Cancer | - | - |
Standard-of-Care | Phase 2 | HER2-positive Early Breast Cancer | - | - |
Durvalumab + Tremelimumab + metronomic Vinorelbine | Phase 2 | Advanced Solid Tumours | - | - |
rAd26-S | Phase 2 | COVID-19 | - | - |
Durvalumab (Cohort 1-3) | Phase 2 | Urothelial Carcinoma | - | - |
AZD1775 | Phase 2 | Uterine Cancer | - | - |
Lymphodepleting chemotherapy | Phase 2 | Refractory Aggressive B-cell Lymphomas | - | - |
Testosterone Enanthate | Phase 2 | Castration-Resistant Prostate Carcinoma | - | - |
Benralizumab 100 mg | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Vigil | Phase 2 | Breast Cancer | - | - |
vandetanib induction | Phase 2 | Lung Cancer | - | - |
AZD4017 and prednisolone | Phase 2 | Iatrogenic Cushing's Disease | - | - |
TEW-7197 | Phase 2 | Non-Small Cell Lung Cancer Metastatic | - | - |
Physicians Choice systemic chemotherapy | Phase 2 | Breast Cancer | - | - |
DS-8201a | Phase 2 | Colorectal Neoplasm | - | - |
AZD5363 | Phase 2 | Non-small Cell Lung Cancer Metastatic | - | - |
Neoantigen DNA vaccine | Phase 2 | Extensive-stage Small Cell Lung Cancer | - | - |
Durvalumab and Tremelimumab | Phase 2 | Metastatic Adult Soft Tissue Sarcoma | - | - |
AZD4547 / anastrozole or letrozole | Phase 2 | Breast Cancer | - | - |
Carboplatin or Cisplatin | Phase 2 | Small Cell Lung Cancer | - | - |
Bevespi | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Formoterol/Budesonide | Phase 2 | Obstructive Airway Disease | - | - |
Olaparib Pill | Phase 2 | High Grade Serous Carcinoma | - | - |
carboplatin AUC 2/paclitaxel | Phase 2 | Esophageal Adenocarcinoma | - | - |
CFI-400945 | Phase 2 | Breast Cancer | - | - |
AZD4045 | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
cis Platinum | Phase 2 | Lung Cancer Stage II | - | - |
AZD8931 | Phase 2 | Metastatic Colorectal Cancer | - | - |
Metoprolol | Phase 2 | Breast Cancer | - | - |
budesonide/formoterol, 2x 200/6 microgram. 4 times daily | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Gefitinib retreatment | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Fulvestrant + ZACTIMA | Phase 2 | Metastatic Breast Cancer | - | - |
Dapagliflozin 10Mg Tab | Phase 2 | Chronic Kidney Diseases | - | - |
Chemoradiotherapy arm | Phase 2 | Oropharyngeal Squamous Cell Carcinoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ASTRAZENECA PLC's drug pipeline?→
CatalystAlert tracks 347 drug candidates in ASTRAZENECA PLC's (AZNCF) pipeline across Phase 3, Phase 2. Its lead program is Goserelin acetate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ASTRAZENECA PLC's next FDA catalyst?→
ASTRAZENECA PLC's (AZNCF) next tracked catalyst is a Phase 2 expected September 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AZNCF biotech catalysts?→
Add AZNCF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ASTRAZENECA PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.